CD44 and central nervous system cancer: Gao et al. developed nanosuspensions (NS) cloaked with C6 glioma membranes and loaded with 10-hydroxycamptothecin (HCPT-NS/CCM) [54] or paclitaxel (CCM-(PTX)NS) [55], both of which retained key membrane markers CD47 and CD44, as confirmed via western blot.